Previous studies have also highlighted the role of the MAPK signaling pathway, with the combination of BRAF (dabrafenib), EGFR (panitumumab), and MEK (trametinib) inhibitors showing promise in BRAF V600E mutated CRC [[24], [25], [26]]. The gene discussed is BRAF; the disease is colorectal carcinoma.